Supplementary file 2_Efficacy and safety of immune checkpoint inhibitors combined with ant

A 2026 systematic review and meta-analysis by Dezhi Zhang, aggregating data from 11 clinical trials involving 1,491 patients with persistent, recurrent, or metastatic cervical cancer. The study evaluates the efficacy and safety of combining immune checkpoint inhibitors with anti-angiogenic agents, reporting outcomes including overall survival, progression-free survival, and adverse event rates. The supporting document is available under a CC-BY-4.0 license.

Use Cases

• Conducting a secondary meta-analysis based on the pooled hazard ratios and risk ratios for overall and progression-free survival.
• Evaluating the safety profile of combination therapies based on the reported rates of severe adverse events (grade ≥3).
• Comparing treatment efficacy between randomized controlled trials and single-arm studies based on the reported objective response rates.
• Assessing the robustness of clinical findings for first-line treatment using the sensitivity analysis results mentioned in the description.

Strengths

• Aggregates data from 11 clinical trials, including 3 randomized controlled trials and 8 single-arm trials.
• Includes outcome data for 1,491 patients with advanced cervical cancer.
• Reports specific statistical measures, including hazard ratios, confidence intervals, and p-values for key efficacy endpoints.

Limitations

• The primary data file is a DOCX document, which may require manual extraction of structured data for computational analysis.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for direct machine learning applications.

Provenance

Source

Systematic review of studies from PubMed, Embase, Cochrane Library, Web of Science, and Scopus.

Collection Method

Meta-analysis of published clinical trial data.

Freshness

Last updated 2026-05-21 05:34:06.